- PharmaCell B.V. -
Alexander Vos (1962) has 20 years of leadership experience in the pharma and biotech industry. Following his graduate studies of pharmacy and pharmacology in Amsterdam, Netherlands, and at the Mayo Clinic in the United States, he obtained a MBA from Stanford University in the United States (1989). After completing his studies, Alexander Vos spent five years as a strategy consultant working for the international pharmaceutical practice of McKinsey & Co. He subsequently worked at Genzyme Therapeutics Europe, holding several executive positions such as European Marketing Director and Director of Business Development, before assuming global responsibility for the joint venture between Genzyme Corporation and Pharming NV, which pursued the goal of developing an innovative therapy for a genetic muscular disease. From 2000 to 2004, Mr. Vos served as Chief Executive Officer of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Before joining PharmaCell, he worked for PAION AG, where he was a Member of the Management Board (“Vorstand”) and Chief Operating Officer. PAION is a clinical stage biopharmaceutical company based in Aachen (Germany) and Cambridge (UK) that is listed on the Frankfurt Stock Exchange.
Sönke Brunswieck’s has 15 years international marketing, sales and business development experience covering the full range of Life Science industry – Pharmaceutical, Diagnostic, Medical Device and Biotechnology Industry. After starting in Marketing and Sales at Pharmacia & Upjohn, GlaxoWellcome and SmithKlineBeecham in Germany, he moved to the specialty diagnostic company Innogenetics based in Gent, Belgium. In 2002 he joined CellGenix GmbH (based in Freiburg, Germany) the leading manufacturer of GMP reagents for the cell therapy industry. At CellGenix he held the position of Director Marketing & Sales. Over the course of more than 10 years he has been responsible for the creation and successful growth of the market for GMP-reagents as used in cell therapy on a global basis. After studying Biology at the Technical University Munich and Max Planck Institute of Psychiatry he obtained his PhD in Neurobiology at the Klinikum Rechts der Isar in Munich.
Registered as an EU QP as per EU Directive
Hans joined PharmaCell as Director of Quality in January 2015 and is responsible for all aspects of Quality Assurance and Quality Control for the company.
Hans has over 15 years experience in the pharmaceutical and biopharmaceutical industry and has earned his PhD in Molecular Biology in 1999 at the University of Amsterdam. He started his career at Selborne Biological Services Pty Ltd. (Tasmania, Australia) in the position as Quality Assurance Manager. After his return to the Netherlands he spent his career as a Quality Executive in the (bio)pharmaceutical industry. From 2000 to 2004 Hans held responsibility for the Quality Assurance department of Banner Pharmacaps – Patheon Inc., and since 2003 acted as a Qualified Person. In 2004 he joined Synthon BV as a Qualified Person for the commercial production of several generic products. In 2007 he was appointed to the start-up team of Synthon Biopharmaceuticals where in 2009 he was appointed to head the Quality Assurance and Quality Control departments in addition to his role as Qualified Person. In this latter role he was responsible for the implementation and Dutch regulatory approval of the quality system at the site, enabling the manufacture of a monoclonal biosimilar product as well as an Antibody-Drug Conjugate to perform clinical trials.
Ruben joined the Production Department of PharmaCell in 2011 and is responsible for all aspects of Manufacturing and Warehousing in the company.
Ruben has over 10 years experience in the (bio)pharmaceutical and medical device industry and graduated as a MSc in Biotechnology in 2003 at Wageningen University in the Netherlands. Previous to joining PharmaCell he held supervisory positions in the manufacturing departments of Oculus Innovative Sciences B.V. producing a topical disinfectant with wound healing features and Solvay Biologicals B.V. producing a cell based influenza vaccine. In both companies Ruben was involved in the market introduction trajectory of their novel products.
Head of Facilities, Engineering & ICT
Joined in 2016, Jaco is responsible for the maintenance of the facility and equipment, calibration and validation activities, as well as the ICT infrastructure.
He has more than 10 years’ experience in the pharmaceutical industry, with previous positions at DSM Biologics and Patheon Biologics. These included tenure as senior Process Engineer, R&D Project Manager and Maintenance and Technology Support Manager. He was part of the core team designing the BPA Pharmaceutical facility in Brisbane, Australia. The facility was recognized with the ISPE Facility of the year award in 2014 in the category Process Innovation.
Holds a Masters’ degree in Biochemical Engineering from the Technical University of Bratislava.
Has more than 20 years’ experience as a HR Manager / Business Partner. She joined PharmaCell in May 2015. She started her career as a consultant at a recruitment agency. After that she worked as HR Manager in an international high tech environment (medical devices). In the beginning she was only responsible for the Netherlands and Belgium and later on she was responsible for the UK and Germany as well.
She studied personnel management (bachelor degree) after her pre university study and later on she finished a post bachelor education in Business Administration.
Casper Bruens brings a broad experience in areas as diverse as materials, electronics, medtech and biotech. He has been in venture capital since 2002, serving as a Senior Investment Manager with DSM Venturing, Director of Limburg Ventures and more recently, Chemelot Ventures. In these capacities he was involved in a large number of investments and has acted as a board member and/or shareholder for multiple portfolio companies. Before his involvement in venture capital Casper held various positions in international BtB marketing, sales and new business. He studied Business Economics at Tilburg University (Netherlands) and Indiana University (Bloomington, USA).
Frank P. Luyten, MD, PhD is board certified Rheumatologist, tenured full Professor and Head of the Division of Rheumatology at the University Hospitals Leuven; Director of the Laboratory for Skeletal Development and Joint Disorders and of Prometheus, the Tissue Engineering Division at the KU Leuven; also Chairman of the Department of Musculoskeletal Sciences at the KU Leuven, Belgium. He obtained his MD, PhD degree and Board Certification in Rheumatology at the University of Ghent, Belgium. He spent his Postdoctoral Training at the National Institute of Dental Research, National Institutes of Health, Bethesda, MD, USA. He became subsequently group leader of the Developmental Biology Unit at the Bone Research Branch, NIDR, NIH, Bethesda, USA.Frank Luyten is also founder, scientific and medical advisor, and member of the Board of Directors of TiGenix, a Biotech spin-off of the Universities of Leuven and Ghent. He serves as advisor and board member of other biotech companies in the field of Regenerative Medicine.
Mr. Pieter ter Kuile most recently served as Vice-Chairman of Kempen & Co, a boutique investment bank with a leading position in biotechnology investment banking in Northern Europe. He has been engaged in the area of Corporate Finance at Kempen & Co since 1993. Prior to joining Kempen, he worked at McKinsey & Co as a strategy consultant. Mr. ter Kuile holds a law degree from the University of Amsterdam and an MBA from the Harvard Business School.
Mr. Hans Preusting is Chief Business Officer at UniQure. Prior to UniQure he served as VP Business Development and Operations (including Manufacturing) for UniQure predecessor company AMT. He jointed AMT in 2006 from Solvay Pharmaceuticals where he held responsibility as Director influenza Vacine Manufacturing. Prior to Solvay he held executive positions at DSM Biologics (a Contract Manufacturing Organization) and as Sr. Scientist and Process Engineer at DSM-Gist Brocades. Mr. Preusing holds a MSc and a PhD degree in BioChemistry from the University of Groningen and an MBA from Rotterdam School of Management.
Mr. Daan van den Noort brings over 25 years of experience from the pharmaceutical and biotechnology industry in Europe as a manager and venture capitalist. He served as General Manager for Genentech, Asta Medica and Ferring in The Netherlands. From 2001 to 2011 he acted as the Chief investment Officer of the Biotech Turnaround Fund. He serves on several international boards of investment companies active in the biopharmaceutical industry. Mr van den Noort holds an MD degree from the Free University of Amsterdam.